Belite Bio (BLTE) Stock Overview
A clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
BLTE Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Belite Bio, Inc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$63.59 |
| 52 Week High | US$86.53 |
| 52 Week Low | US$43.70 |
| Beta | -1.51 |
| 1 Month Change | 7.71% |
| 3 Month Change | 3.43% |
| 1 Year Change | 30.41% |
| 3 Year Change | 89.82% |
| 5 Year Change | n/a |
| Change since IPO | 500.47% |
Recent News & Updates
Recent updates
We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
Jul 02
We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow
Sep 26Are Investors Undervaluing Belite Bio, Inc (NASDAQ:BLTE) By 45%?
Jul 03We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely
Mar 20An Intrinsic Calculation For Belite Bio, Inc (NASDAQ:BLTE) Suggests It's 49% Undervalued
Jan 10Belite Bio, Inc's (NASDAQ:BLTE) Intrinsic Value Is Potentially 25% Below Its Share Price
Jul 31We're Not Worried About Belite Bio's (NASDAQ:BLTE) Cash Burn
May 03Belite Bio down 21% after disappointing mid-stage results of rare eye disease candidate
Oct 03Belite Bio receives approval of begin LBS-008 phase 3 trial in China
Sep 16Belite Bio adds 15% as pivotal trial for lead asset starts in U.S.
Aug 22Belite Bio GAAP EPS of -$0.23 beats by $0.05
Aug 12Belite Bio (NASDAQ:BLTE) Is In A Good Position To Deliver On Growth Plans
Aug 01Belite seeks FDA nod to proceed with phase 3 trial of genetic eye disease treatment
Jul 19Shareholder Returns
| BLTE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 6.6% | 3.6% | 1.5% |
| 1Y | 30.4% | -6.8% | 17.7% |
Return vs Industry: BLTE exceeded the US Pharmaceuticals industry which returned -6.8% over the past year.
Return vs Market: BLTE exceeded the US Market which returned 17.7% over the past year.
Price Volatility
| BLTE volatility | |
|---|---|
| BLTE Average Weekly Movement | 6.3% |
| Pharmaceuticals Industry Average Movement | 10.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: BLTE has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: BLTE's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 25 | Tom Lin | www.belitebio.com |
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an anti-retinol-binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout.
Belite Bio, Inc Fundamentals Summary
| BLTE fundamental statistics | |
|---|---|
| Market cap | US$2.02b |
| Earnings (TTM) | -US$42.55m |
| Revenue (TTM) | n/a |
Is BLTE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BLTE income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$42.55m |
| Earnings | -US$42.55m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BLTE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/07/29 21:48 |
| End of Day Share Price | 2025/07/29 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Belite Bio, Inc is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bruce Jackson | Benchmark Company |
| Jennifer Kim | Cantor Fitzgerald & Co. |
| Yi Chen | H.C. Wainwright & Co. |